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Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S146virus (EBV) is a gammaherpes virus that is reactivated from
latent to lytic cycle and can cause aggressive lymphomas
known as post transplant lymphoproliferative disorder
(PTLD) in immunocompromised hosts. We attempted to
distinguish immune reconstitution proﬁles in double UCBT
recipients who developed EBV viremia from those who did
not. Thirty-one patients with hematologic malignancies
received dUCBT with melphalan, ﬂudarabine, ATG condi-
tioning and tacrolimus plus sirolimus for GvHD prophylaxis.
During the ﬁrst 12 months after dUCBT, 14 of 31 (45%) pa-
tients developed EBV viremia and four (13%) developed
PTLD. At one month after dUCBT, patients with EBV viremia
displayed higher numbers of CD19+ B cells (p¼0.04) and
CD4+CD25+ Treg cells (p¼0.03) compared with patients
who never became viremic. Surprisingly, EBV viremia
correlated with increased numbers of CD3+ (p¼0.04), CD4+
(p¼0.015) and CD8+ (p¼0.021) T cells, but this response was
ineffective at controlling the virus. One explanation for this
unexpected result might be skewing towards a late effector
memory T cell phenotype, a stage in which T cells are inca-
pable of mounting protective immune responses. We
examined naïve vs. memory T cell distribution and deter-
mined that patients who developed EBV reactivation had
higher numbers of memory cell subsets (CD4+CD45RO+,
p¼0.023; CD8+CD45RO+, p¼0.019) at two months after
dUCBT. Analysis of repertoire diversity by deep-sequencing
on PCR-ampliﬁed CDR3 regions of the TCRb gene using the
ImmunoSEQ assay showed a more diverse TCR repertoire, as
determined by higher entropy (p¼0.03) and lower clonality
(p¼0.03), among patients who did not develop EBV reac-
tivation. Assessment of SCF and IL-7, critical regulators of
hematopoietic stem cell and naïve T cell homeostasis,
respectively, showed that patients without EBV viremia had
higher levels of SCF (p¼0.0016) and IL-7 (p¼0.046)
compared with patients who developed viremia and PTLD.
Our ﬁndings suggest that control of EBV reactivation after
dUCBT might be linked to the support of naïve T cell ho-
meostasis, which enables maintenance of a diverse TCR
repertoire.202
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for Cellular Therapy, Orlando, FLIntroduction: Plerixafor is a reversible CXCR4 antagonist
that has been approved by the food and drug administration
for autologous hematopoietic stem cell mobilization in pa-
tients withmultiplemyeloma and non-hodgkin’s lymphoma.
Patients mobilized with Plerixafor were shown to have a
higher proportion of primitive stem cells (CD34+/CD133+/
CD38-), CD4+ T cells and Natural killer cells (CD3-/CD16+/
CD56+) in the graft composition when compared to patients
mobilized with chemotherapy plus G-CSF alone. We inves-
tigated the effect of Plerixafor on immune reconstitution
at thirty and sixty days post autologous stem cell
transplantation.
Methods: Patients eligible for autologous stem cell trans-
plantation were enrolled on a single arm prospective im-
mune reconstitution trial. A complete blood count,
differential and lymphocyte ﬂow cytometry panel (T cell, NK
cell and B cell markers) was checked on Days 30 and 60 post
autologous transplantation. Stem cell mobilization was car-
ried per our institutional standards. All patients received
subcutaneous G-CSF at a dose of 10 mg per kilogram body
weight for four consecutive days. On Day4, patient with a
peripheral CD34 count of 20/ml received plerixafor 0.24mg/
kg. Collection was started on day 5 and continued till
collection goal was reached or patient failed to get the
minimal cell dose after 4 consecutive days of pheresis.
Results: 49 patients were enrolled during the period from
September 2010 till May 2012. Median age at time of
transplantation was 54 years (range 21;72 years). 35 pa-
tients had multiple myeloma and 14 had non-Hodgkin’s
lymphoma. 16 patients received GCSF alone (group A) and
33 had plerixafor plus GCSF (group B) for mobilization. All
patients achieved the minimum target of CD34 collection.
The mean number of collection days was 1.9 and 1.4 days
(p¼0.05) with a total collection dose of 7.76 and 7.61 CD34
x106/Kg for groups A and B respectively. The percentage
proportion of CD34 in the aphaeresis product was 0.73%
and 0.75% (p¼0.9) for group A and B. Total infused CD34
dose was similar in both groups (4.88 and 4.56 CD34x106/
kg) with time to engraftment of 11.68 vs 11.69 days for
neutrophils and 20.62 vs 21.39 for platelets in groups A and
B respectively. There was no difference between day 30
absolute lymphocyte count (1.09 vs 1.44 x103/mm3
p¼0.18); Absolute NK cell (0.31 vs 0.35 x103/ml; p¼0.51);
absolute T cell count (0.71 vs 0.96 x103/ml p¼0.33) and
absolute neutrophil count (2.98 vs 2.63 x103/mm3 p¼0.37).
The cell count recovery was also not signiﬁcantly different
when analyzed per disease (myeloma or non-Hodgkin’s
lymphoma) and at day 60.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S147Conclusion: Our study shows that patient mobilized with
plerixafor and G-CSF have similar immune reconstitution at
30 and 60 days post autologous transplantation compared to
patients mobilized with G-CSF alone.LATE EFFECTS/QUALITY OF LIFE/PSYCHOSOCIAL ISSUES
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Background: HCT is a lengthy, complex procedure with the
potential for decreased quality of life, transplant related
mortality, relapsed disease, and graft-versus-host disease.
Psychosocial assessments are a part of the overall HCT eval-
uation process, but there are very few validated psychosocial
instruments for this patient population. Recently, the SIPAT
has been shown to predict outcomes in solid organ trans-
plantation. A retrospective pilot study was performed on 25
consecutive HCT patients to investigate whether SIPAT re-
sults correlated with HCT outcomes.
Methods: The retrospective pilot study was modeled after
methodology published in any earlier SIPAT study conducted
by JR Maldonado (Psychosomatics, 2012). Two experienced
HCT reviewers, a physician and a social worker, and an
inexperienced reviewer, a transplant coordinator, conducted
the retrospective chart review, completing the SIPAT for 25
consecutive HCT recipients at the University of Virginia be-
tween January and October 2012. A clinical research coor-
dinator independently reviewed each patient’s medical
records and interviewed transplant coordinators to record
HCT recipient outcomes.
Results: HCT recipients (median age 52, 56% male) received
HCT’s for myeloma, lymphoma and leukemia. 14 recipients
received an allogeneic transplant, while 11 received an
autologous one. The inter-rater reliability between the
SIPAT reviewers was inconsistent. 2 reviewers correlated
well (R¼.84), while the other correlations between re-
viewers were weak (R¼.62 and R¼.55). It was noted that
there was a response shift in SIPAT reviewer 3 to lower
scores, indicating potential bias in reviewers 1 and 2 due to
prior patient exposure. To test possible associations of
psychosocial assessments with recipient outcomes, indi-
vidual reviewer SIPAT scores were plotted. These indicated
higher assessment scores were associated with poorer so-
cial support and compliance, and increased drug relapses,
and psychiatric symptoms. Other outcome measures such
as graft failure, treatment related mortality, re-hospitali-
zation and disease relapse failed to show a relationship
with SIPAT scores.
Conclusion: SIPAT scores may indicate positive relation-
ships between HCT psychosocial assessments and various
psychosocial outcomes. Due to the limited number of
transplant recipients in the retrospective review, it was
not possible to completely blind the experiencedreviewers. Bias may have been introduced resulting in
higher scores for these reviewers compared to the third
reviewer, who was new to the program. Additionally, the
poor inter-rater reliability of the SIPAT (in spite of educa-
tion and practice) may have arisen from the challenges of
scoring patients retrospectively through chart reviews, as
the program’s psychosocial assessment was not as detailed
as the SIPAT. These issues can be addressed in future
prospective studies.204
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Background: Through the use of an electronic medical re-
cord (EMR) based system, care managers, and single provider
physician oversight, we previously reported high concor-
dance rates of post hematopoietic stem cell transplant
(HSCT) screening based on ASBMT guidelines in a commu-
nity based, multi-facility care delivery system.
Objective: To demonstrate that case management in a
vertically integrated, EMR based community practice span-
ning 9 medical centers in a large metropolitan region can
consistently promote high concordance rates with published
ASBMT guidelines and lead to timely recognition of common
transplant associated complications.
Methods: Retrospective chart review of 74 consecutive pe-
diatric HSCT survivors (0-18yrs) from 2005-2013 looking for
concordance rates with 2012 ASBMT late effects guidelines.
The frequency of thyroid dysfunction, cataracts, pulmonary
disease, and ovarian dysfunction were noted as well as the
mean time to development. Majority of patients were treated
with fractionated TBI and therefore were at high risk of
developing late effects.
Results: We observed a sustained high level of concordance
(>90%) with screening guidelines in the period after a pop-
ulation care management approach was implemented
(2009-2013). This led to the timely identiﬁcation and man-
agement of HSCT associated complications.
Conclusion: An EMR based, vertically integrated health care
system facilitates effective community based post-HSCT
survivorship care in the pediatric population.205
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Background: Patients of stem cell transplantation (SCT) may
experience long-term symptoms that impact quality of life
and adjustment. Employment status has been identiﬁed as
an important marker for post-transplant adjustment.
